Outgoing Medtronic (NYSE:MDT) chief executive Bill Hawkins is predicting only mild pain when the Food & Drug Administration unveils changes to the 510(k) rules governing approval for most medical devices.
Hawkins told attendees at the JP Morgan Healthcare Conference this week in San Francisco, that updates to 510(k) “will be neutral to slightly negative” for those trying to create new innovative medical devices, according to EE Times.